key: cord-0686256-b4ov63x3
authors: Peled, Yael; Ram, Eilon; Mandelboim, Michal; Lavee, Jacob; Sternik, Leonid; Segev, Amit; Wieder‐Finesod, Anat; Halperin, Rebecca; Indenbaum, Victoria; Levy, Itzchak; Patel, Jignesh; Raanani, Ehud; Lustig, Yaniv; Rahav, Galia
title: Waning humoral immune response to the BNT162b2 vaccine in heart transplant recipients over 6 months
date: 2022-03-01
journal: Am J Transplant
DOI: 10.1111/ajt.16998
sha: 559da867d193b8f320ac0ae3826e1c7e6e4d5a2e
doc_id: 686256
cord_uid: b4ov63x3

nan

To the Editor:

A third booster dose of mRNA vaccines, shown to elicit enhanced immune responses in solid organ transplant (SOT) recipients, 1,2 has been recommended for immunocompromised patients, but the optimal interval between doses to ensure long-lasting protective immunity has not been determined. We therefore conducted a six-month longitudinal prospective study of antibody kinetics in heart trans- 

BNT162b2 vaccination in heart transplant recipients: clinical experience and antibody response

Third dose of the BNT162b2 vaccine in heart transplant recipients: immunogenicity and clinical experience

A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Function is more reliable than quantity to follow up the humoral response to the receptor-binding domain of SARS-CoV-2-spike protein after natural infection or COVID-19 vaccination